WO2006134190A3 - Agentes y métodos basados en el uso del dominio eda de la fibronectina - Google Patents

Agentes y métodos basados en el uso del dominio eda de la fibronectina Download PDF

Info

Publication number
WO2006134190A3
WO2006134190A3 PCT/ES2006/000343 ES2006000343W WO2006134190A3 WO 2006134190 A3 WO2006134190 A3 WO 2006134190A3 ES 2006000343 W ES2006000343 W ES 2006000343W WO 2006134190 A3 WO2006134190 A3 WO 2006134190A3
Authority
WO
WIPO (PCT)
Prior art keywords
eda domain
fibronectin
agents
methods based
eda
Prior art date
Application number
PCT/ES2006/000343
Other languages
English (en)
French (fr)
Other versions
WO2006134190A8 (es
WO2006134190A2 (es
Inventor
Claude Leclerc
Sagastibelza Juan Jose Lasarte
Ayala Marta Gorraiz
Valtuena Jesus Prieto
Original Assignee
Proyecto Biomedicina Cima Sl
Claude Leclerc
Sagastibelza Juan Jose Lasarte
Ayala Marta Gorraiz
Valtuena Jesus Prieto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007015935A priority Critical patent/MX2007015935A/es
Priority to CA2612151A priority patent/CA2612151C/en
Priority to DK06794018.9T priority patent/DK1913954T3/da
Priority to AU2006259041A priority patent/AU2006259041B2/en
Application filed by Proyecto Biomedicina Cima Sl, Claude Leclerc, Sagastibelza Juan Jose Lasarte, Ayala Marta Gorraiz, Valtuena Jesus Prieto filed Critical Proyecto Biomedicina Cima Sl
Priority to EP06794018A priority patent/EP1913954B8/en
Priority to US11/922,148 priority patent/US9155783B2/en
Priority to PL06794018T priority patent/PL1913954T3/pl
Priority to CN2006800293241A priority patent/CN101287487B/zh
Priority to BRPI0611782-1A priority patent/BRPI0611782A2/pt
Priority to ES06794018T priority patent/ES2392659T3/es
Priority to JP2008516349A priority patent/JP4970435B2/ja
Publication of WO2006134190A2 publication Critical patent/WO2006134190A2/es
Publication of WO2006134190A3 publication Critical patent/WO2006134190A3/es
Publication of WO2006134190A8 publication Critical patent/WO2006134190A8/es
Priority to US14/835,764 priority patent/US20160215039A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere al empleo de un polipéptido que comprende una secuencia correspondiente al dominio EDA de la fibronectina, un fragmento de dicho dominio EDA capaz de unirse a TLR4, o una variante de dicho dominio EDA o fragmento que es capaz de unirse a TLR4 y presenta una homología mayor del 70% con cualquier forma o fragmento natural del dominio EDA, en la elaboración de un agente inmunoestimulador. La presente invención se refiere también a los métodos de producción y las aplicaciones del citado agente.
PCT/ES2006/000343 2005-06-13 2006-06-13 Agentes y métodos basados en el uso del dominio eda de la fibronectina WO2006134190A2 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US11/922,148 US9155783B2 (en) 2005-06-13 2006-06-13 Agents and methods based on the use of the EDA domain of fibronectin
DK06794018.9T DK1913954T3 (da) 2005-06-13 2006-06-13 Anvendelse af fibronectins EDA domæne
AU2006259041A AU2006259041B2 (en) 2005-06-13 2006-06-13 Agents and methods based on the use of the EDA domain of fibronectin
CN2006800293241A CN101287487B (zh) 2005-06-13 2006-06-13 基于使用纤连蛋白eda结构域的试剂和方法
EP06794018A EP1913954B8 (en) 2005-06-13 2006-06-13 Use of the eda domain of fibronectin
CA2612151A CA2612151C (en) 2005-06-13 2006-06-13 Agents and methods based on the use of the eda domain of fibronectin
PL06794018T PL1913954T3 (pl) 2005-06-13 2006-06-13 Zastosowanie domeny eda fibronektyny
MX2007015935A MX2007015935A (es) 2005-06-13 2006-06-13 Agentes y metodos basados en el uso del dominio eda de la fibronectina.
BRPI0611782-1A BRPI0611782A2 (pt) 2005-06-13 2006-06-13 uso de um polipeptìdio, vetor proteìnico, uso do mesmo, ácido nucléico modificado, vetor de expressão, célula hospedeira de expressão, método para produzir um vetor proteìnico, uso de um ácido nucléico modificado e de um polipeptìdio e composição farmacêutica
ES06794018T ES2392659T3 (es) 2005-06-13 2006-06-13 Uso del dominio EDA de fibronectina
JP2008516349A JP4970435B2 (ja) 2005-06-13 2006-06-13 フィブロネクチンのｅｄａドメインの使用を基にした剤および方法
US14/835,764 US20160215039A1 (en) 2005-06-13 2015-08-26 Agents and methods based on the use of the eda domain of fibronectin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501412A ES2291071B1 (es) 2005-06-13 2005-06-13 Agentes y metodos basados en el uso del dominio eda de la fibronectina.
ESP200501412 2005-06-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/922,148 A-371-Of-International US9155783B2 (en) 2005-06-13 2006-06-13 Agents and methods based on the use of the EDA domain of fibronectin
US14/835,764 Division US20160215039A1 (en) 2005-06-13 2015-08-26 Agents and methods based on the use of the eda domain of fibronectin

Publications (3)

Publication Number Publication Date
WO2006134190A2 WO2006134190A2 (es) 2006-12-21
WO2006134190A3 true WO2006134190A3 (es) 2007-02-22
WO2006134190A8 WO2006134190A8 (es) 2008-01-31

Family

ID=37532656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000343 WO2006134190A2 (es) 2005-06-13 2006-06-13 Agentes y métodos basados en el uso del dominio eda de la fibronectina

Country Status (14)

Country Link
US (2) US9155783B2 (es)
EP (1) EP1913954B8 (es)
JP (1) JP4970435B2 (es)
CN (1) CN101287487B (es)
AU (1) AU2006259041B2 (es)
BR (1) BRPI0611782A2 (es)
CA (1) CA2612151C (es)
DK (1) DK1913954T3 (es)
ES (2) ES2291071B1 (es)
MX (1) MX2007015935A (es)
PL (1) PL1913954T3 (es)
PT (1) PT1913954E (es)
RU (1) RU2430738C2 (es)
WO (1) WO2006134190A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325790A (zh) 2008-12-03 2012-01-18 西马生物医学计划公司 应用酚可溶性调控蛋白研制疫苗
WO2011029980A1 (es) 2009-09-11 2011-03-17 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
US20130108661A1 (en) * 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
WO2011101332A1 (en) * 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
CA2854437A1 (en) * 2010-11-04 2012-05-10 The Board Of Regents Of The University Of Oklahoma Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same
WO2012123269A1 (en) * 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
WO2014136845A1 (ja) * 2013-03-06 2014-09-12 タカラバイオ株式会社 成熟樹状細胞集団の製造方法
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
WO2018162450A1 (en) * 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
AU2021341521A1 (en) 2020-09-14 2023-03-30 Boehringer Ingelheim International Gmbh Heterologous prime boost vaccine
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
WO2023174998A1 (en) 2022-03-16 2023-09-21 Boehringer Ingelheim International Gmbh Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188446A1 (en) * 2000-09-15 2002-03-20 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108898A (en) * 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
WO2000076456A2 (en) * 1999-06-14 2000-12-21 The General Hospital Corporation Modulators of fibrosis
JP2005523887A (ja) * 2002-01-03 2005-08-11 シエーリング アクチエンゲゼルシャフト 腫瘍の新しい診断および治療方法
FR2855758B1 (fr) * 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188446A1 (en) * 2000-09-15 2002-03-20 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KAISHO T. ET AL.: "Toll-like receptors as adjuvant receptors", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1589, no. 1, February 2002 (2002-02-01), pages 1 - 13, XP004344849 *
LUTZ M. ET AL.: "Immature, semi-immature and fully mature dendritic cells: which signals induce tolerance or immunity?", TRENDS IN IMMUNOLOGY, vol. 23, no. 9, September 2002 (2002-09-01), pages 445 - 449, XP004377436 *
MARTIN P. ET AL.: "Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in Hepatitis C virus NS3 antigen", JOURNAL OF MEDICAL VIROLOGY, vol. 74, no. 3, November 2004 (2004-11-01), pages 397 - 405, XP008078477 *
MURO A.F. ET AL.: "Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and 5' splicing site", FEBS LETTERS, vol. 437, no. 1-2, 1998, pages 137 - 141, XP004258506 *
OKAMURA Y. ET AL.: "The extra domain A of fibronectin activates Toll-like receptor 4", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 13, March 2001 (2001-03-01), pages 10229 - 10233, XP003008523 *
PAOLELLA G. ET AL.: "Sequence analysis and in vivo expression show that alternative splicing of ED-B and ED-A regions of the human fibronectin gene are independent events", NUCLEIC ACIDS RESEARCH, vol. 16, no. 8, April 1988 (1988-04-01), pages 3545 - 3557, XP000910295 *

Also Published As

Publication number Publication date
CA2612151C (en) 2015-01-13
CN101287487A (zh) 2008-10-15
AU2006259041B2 (en) 2012-02-02
EP1913954A2 (en) 2008-04-23
US20160215039A1 (en) 2016-07-28
DK1913954T3 (da) 2012-11-26
WO2006134190A8 (es) 2008-01-31
JP2008543301A (ja) 2008-12-04
CA2612151A1 (en) 2006-12-21
ES2392659T3 (es) 2012-12-12
US20090220532A1 (en) 2009-09-03
EP1913954B8 (en) 2012-09-19
PL1913954T3 (pl) 2013-01-31
AU2006259041A1 (en) 2006-12-21
ES2291071A1 (es) 2008-02-16
PT1913954E (pt) 2012-11-19
BRPI0611782A2 (pt) 2010-09-28
US9155783B2 (en) 2015-10-13
EP1913954B1 (en) 2012-08-08
WO2006134190A2 (es) 2006-12-21
CN101287487B (zh) 2013-02-06
JP4970435B2 (ja) 2012-07-04
MX2007015935A (es) 2008-04-21
RU2430738C2 (ru) 2011-10-10
EP1913954A4 (en) 2011-01-12
RU2008100242A (ru) 2009-07-20
ES2291071B1 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
WO2007060117A3 (de) Chimäre keratinbindende effektorproteine
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
MX2009013083A (es) Metodos para mejorar multiples propiedades de proteina.
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2004078120A3 (en) Collagen compositions and biomaterials
TW200501277A (en) Nanofiber surfaces for use in enhanced surface area applications
AU304952S (en) Toothbrush
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
WO2006015258A3 (en) Methods and compositions related to argonaute proteins
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2006135793A3 (en) Protein engineering with analogous contact environments
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
WO2007053512A3 (en) Novel protein transduction domains and uses therefor
WO2006002856A3 (de) Verbund umfassend mindestens eine harte komponente und mindestens eine weiche komponente
Durie Doors of perception.
WO2008094945A3 (en) Compounds and methods for modulating protein expression
MX2007011411A (es) Interaccion rage/diaphanous y composiciones relacionadas y metodos.
WO2004072094A3 (en) Hmgb1 modulator binding domain
WO2007078746A3 (en) Computational and/or control systems related to individualized nutraceutical selection and packaging
WO2007086889A3 (en) Tropoelastin isoforms and uses thereof
WO2007127830A3 (en) Dep2 and its uses in major depressive disorder and other related disorders
GB0818080D0 (en) Immunogenic peptides
EP1844065A4 (en) POLYPEPTIDE WITH PYRIDOXIN BIOSYNTHESIS FUNCTION, POLYNUCLEOTIDE FOR CODING THE POLYPEPTIDE AND THEIR USE
Jang et al. Examining the relationship between the types of color selecting behavior and self-esteem in Mabinogi, the on-line game

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680029324.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015935

Country of ref document: MX

Ref document number: 2008516349

Country of ref document: JP

Ref document number: 2612151

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006794018

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006259041

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008100242

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006259041

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006259041

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006794018

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11922148

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611782

Country of ref document: BR

Kind code of ref document: A2